by Laurel Manke | Oct 16, 2025 | 3PL, Cold Chain, Ryan Oppel
When Risk Becomes Reality In specialty pharma, every degree matters—and every delay has a cost. As products become more targeted and high-value—such as cell therapies, controlled medications, and rare biologics—the demand for secure, real-time-monitored cold chain...
by Laurel Manke | Oct 9, 2025 | 3PL, Ryan Oppel
In the pharmaceutical, biotech, and cell & gene therapy (CGT) industries, the quality and viability of temperature-sensitive assets rely on more than insulated packaging and thermal lanes. Today’s cold chain must be resilient, compliant, and capable of scaling...